Anna L. Bula
6 Papers
Anna L. Bula is an academic researcher. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate
Olga Bobiļeva,Raitis Bobrovs,Iveta Kaņepe,Liene Patetko,Gints Kalniņš,M. Sisovs,Anna L. Bula,Solveiga Grinberga,Ma̅rtiņš Borodušķis,Anna Ramata-Stunda,Nils Rostoks,Aigars Jirgensons,Kaspars Tars,Kristaps Jaudzems +13 more
TL;DR: This work designed potential SARS-CoV-2 MTase Nsp14 and Nsp16 inhibitors by using bioisosteric substitution of the sulfonium and amino acid substructures of the cosubstrate S-adenosylmethionine (SAM), which serves as the methyl donor in the enzymatic reaction.
61
dGAE(297-391) tau fragment promotes formation of CTE-like full-length tau filaments
Kristīne Kitoka,Alons Lends,Gytis Kučinskas,Anna L. Bula,Lukas Krasauskas,Vytautas Smirnovas,Rostislav Skrabana,Jozef Hritz,Kristaps Jaudzems +8 more
TL;DR: In this article , the authors used the tau fragment dGAE(297-391), which aggregates spontaneously, to seed the formation of full-length tau filaments.
2
Structural basis for inhibition of the SARS-CoV-2 nsp16 by substrate-based dual site inhibitors.
G. Kalnins,Laura Rudusa,Anna L. Bula,Diana Zelencova-Gopejenko,Olga Bobileva,M. Šišovs,Kaspars Tars,Aigars Jirgensons,Kristaps Jaudzems,Raitis Bobrovs +9 more
TL;DR: Researchers employed X-ray crystallography to study the binding of SAM analogues to SARS-CoV-2 nsp16, obtaining 11 crystal structures, and found that dual-site targeting of SAM and RNA sites enhances inhibitory potential against the virus.
Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening
Raitis Bobrovs,Iveta Kanepe,Nauris Narvaiss,Liene Patetko,G. Kalnins,M. Sisovs,Anna L. Bula,Solveiga Grinberga,Martins Boroduskis,Anna Ramata-Stunda,Nils Rostoks,Aigars Jirgensons,Kaspars Tars,Kristaps Jaudzems +13 more
TL;DR: In this paper, the authors report results from high-throughput virtual screening against these two enzymes, nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agents.
Comprehensive Fragment Screening of the SARS‐CoV‐2 Proteome Explores Novel Chemical Space for Drug Development
Hannes Berg,Maria Alexandra Wirtz Martin,Nadide Altincekic,Islam Alshamleh,Jasleen Kaur Bains,Julius Blechar,Betül Ceylan,Vanessa de Jesus,Karthikeyan Dhamotharan,Christin Fuks,Santosh Lakshmi Gande,Bruno Hargittay,Katharina F. Hohmann,Marie T Hutchinson,Sophie Marianne Korn,Robin Krishnathas,Felicitas Kutz,Verena Linhard,Tobias Matzel,Nathalie Meiser,Anna Niesteruk,Dennis J. Pyper,Linda Schulte,Sven Trucks,Kamal Azzaoui,Marcel J. J. Blommers,Yojana Gadiya,Reagon Karki,Andrea Zaliani,Philip Gribbon,Marcius S. Almeida,Cristiane D. Anobom,Anna L. Bula,Matthias Buetikofer,Ícaro Putinhon Caruso,Isabella C. Felli,Andrea T. Da Poian,Gisele Cardoso Amorim,Nikolaos K. Fourkiotis,Angelo Gallo,Dhiman Ghosh,Francesco Gomes-Neto,Oksana Gorbatyuk,Bing Hao,Vilius Kurauskas,Lauriane Lecoq,Yunfeng Li,N. C. Mebus-Antunes,Miguel Mompeán,T. C. Neves-Martins,Martí Ninot-Pedrosa,Anderson S. Pinheiro,Letizia Pontoriero,Yulia Pustovalova,Roland Riek,Angus Everett Robertson,Marie Jose Abi Saad,Miguel A. Treviño,Aikaterini C. Tsika,Fabio C. L. Almeida,Ad Bax,Katherine A. Henzler-Wildman,Jeffrey S Hoch,Kristaps Jaudzems,Douglas V. Laurents,Julien Orts,Roberta Pieratelli,Georgios A. Spyroulias,Elke Duchardt-Ferner,Jan Ferner,Boris Fuertig,Martin Hengesbach,Frank Löhr,Nusrat S. Qureshi,Christian Richter,Krishna Saxena,Andreas Schlundt,Sridhar Sreeramulu,Anna Wacker,Julia E. Weigand,Julia Wirmer-Bartoschek,Jens Woehnert,Harald Schwalbe +82 more
TL;DR: This investigation provides novel structural and chemical space for structure‐based drug design against the SCoV2 proteome and identify functional moieties (chemotypes) of the ligands occupying these pockets.